Genmab AS (FRA:GE91) Beta: 1.6850 (As of Jun. 24, 2026)


FRA:GE91 Genmab AS FRA:GE91
93 GF Score
Price €21.80
GF Value €29.03
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Genmab AS Beta?

Genmab AS FRA:GE91 +0.93% 93 Beta is 1.6850 as of Jun. 24, 2026. GuruFocus rates FRA:GE91 with a GF Score™ of 93/100 and a GF Value™ of €29.03 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-24), Genmab AS's Beta is 1.6850.


Genmab AS  (FRA:GE91) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Genmab AS Beta Related Terms


Genmab AS Beta Historical Data

* Premium members only.

The historical data trend for Genmab AS's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab AS Beta Chart

Genmab AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 1.35 -0.36 -0.64

Genmab AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.32 1.47 1.72 -0.64 1.50

FRA:GE91 vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Genmab AS's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Beta distribution charts can be found below:

* The bar in red indicates where Genmab AS's Beta falls into.


FRA:GE91
93GF Score
Genmab AS FRA:GE91
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genmab AS Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.6850 mean?
Genmab AS (FRA:GE91) has a Beta of 1.6850 as of Jun. 24, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Genmab AS and its competitors.
Is Genmab AS's Beta too high?
Genmab AS's current Beta is 1.6850. Overall, Genmab AS has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Beta compare to VRTX and REGN?
Genmab AS's Beta of 1.6850 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Genmab AS and its competitors. Genmab AS's current Beta is 1.6850. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (FRA:GE91) is currently considered Modestly Undervalued. The stock's GF Value™ is €29.03, compared to a current price of €21.80 — trading 24.9% below its estimated fair value. The current Beta is 1.6850. Genmab AS's overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Genmab AS (FRA:GE91), the current Beta is 1.6850 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genmab AS (FRA:GE91) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of €21.80 is trading 24.9% below its estimated GF Value™ of €29.03. GuruFocus considers Genmab AS to be Modestly Undervalued.

Key valuation signals for FRA:GE91:

  • Beta: 1.6850
  • GF Value™: €29.03 vs. price of €21.80 (24.9% below fair value)
  • GF Score™: 93/100 with 5 warning signs

No single metric tells the full story. See the FRA:GE91 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
93GF Score

Get the complete analysis for FRA:GE91

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.80
Price
€29.03
GF Value